| Subject: | FDA Issues New Safety Information about Triptans and Selective Serotonin Reuptake Inhibitors (SSRIs) or Selective Serotonin/Norepinephrine Reuptake Inhibitors (SNRIs) |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Mon, 31 Jul 2006 - 12:00 am |
| The FDA has notified healthcare professionals and consumers of new safety information regarding taking medications used to treat migraine headaches, 5-Hydroxytryptamine Receptor Agonists (triptans), together with certain types of antidepressant and mood disorder medications [selective serotonin reuptake inhibitors (SSRIs) and selective serotonin/norepinephrine reuptake inhibitors (SNRIs)]. A life-threatening condition called serotonin syndrome may occur when Triptans are used together with a... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
REFERENCE:
External Links:
|
|
StayAlert!® Virtual Compliance Administrator™ keeps clients informed by email of any changes to Federal regulations, including Joint Commission (TJC, formerly JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG, and many more, and also provides downloadable tools to ensure compliance. StayAlert! is a premium product sold as an annual site-license subscription. With the site license, the client can sign up an unlimited number of users for the email alerts and access to the StayAlert! online regulatory library. Other vendors have components of legislated requirements available online or on CD-ROM. However there is no other product that marries regulatory agency mandates with implementation tools, making the latest compliance information immediately available online. No other product provides an interpretative analysis, followed by a practical application tool, therefore providing users with an immediate solution to compliance problems. StayAlert! includes operational components for healthcare organizations, allowing complete facility compliance with mandated requirements, online. |
|
